Ceria Therapeutics, Inc. is a preclinical biopharmaceutical company headquartered in Tucson AZ and founded in 2019. The company is developing products derived from a platform technology yielding in development for conditions in the critical care, GI, and wound care markets, collectively addressing >$25B market opportunities in the US. Each of Ceria’s products delivers and restores a naturally-occurring RNA molecule (microRNA-146a) that plays a critical role in regulating inflammation. Our products transiently increase this molecule in inflamed tissues resulting in rapid blocking of cytokines and durable resolution of disease in acute conditions characterized by dysregulated inflammation. Our critical care assets address acute lung injury, acute respiratory distress syndrome, acute kidney injury, acute pancreatitis, and toxemic sepsis. Our GI assets address Crohn's disease and ulcerative colitis and our dermatology assets address non-healing diabetic foot ulcers.